Compare WMK & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMK | STOK |
|---|---|---|
| Founded | 1912 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1994 | 2019 |
| Metric | WMK | STOK |
|---|---|---|
| Price | $75.67 | $26.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $46.46 |
| AVG Volume (30 Days) | 128.1K | ★ 758.4K |
| Earning Date | 11-06-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $4,714,573,000.00 | $184,420,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $39.98 |
| P/E Ratio | $37.90 | ★ N/A |
| Revenue Growth | 0.01 | ★ 404.50 |
| 52 Week Low | $59.99 | $20.32 |
| 52 Week High | $83.74 | $40.22 |
| Indicator | WMK | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 51.08 |
| Support Level | $68.17 | $24.21 |
| Resistance Level | $82.50 | $33.61 |
| Average True Range (ATR) | 1.89 | 1.23 |
| MACD | 0.28 | 0.37 |
| Stochastic Oscillator | 43.31 | 76.79 |
Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.